Stock GLTO GALECTO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Galecto, Inc.

Equities

GLTO

US36322Q1076

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 12:16:14 2024-05-08 pm EDT 		5-day change 1st Jan Change
0.7 USD -1.42% Intraday chart for Galecto, Inc. +5.79% -0.07%
May. 01 Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab CI
Apr. 29 Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 316 76.54 29.42 19.52 19.25 - -
Enterprise Value (EV) 1 152.4 13.98 -3.368 19.52 1.153 -52.45 -90.05
P/E ratio -1.64 x -1.48 x -0.47 x -0.5 x -0.59 x -0.39 x -0.34 x
Yield - - - - - - -
Capitalization / Revenue - - - - - - -
EV / Revenue - - - - - - -
EV / EBITDA -4,557,111 x -269,964 x 55,467 x - - - -
EV / FCF -3,990,022 x -266,135 x 78,089 x - - - -
FCF Yield -0% -0% 0% - - - -
Price to Book 1.91 x 0.65 x 0.47 x - - - -
Nbr of stocks (in thousands) 25,261 25,262 25,581 27,113 27,113 - -
Reference price 2 12.51 3.030 1.150 0.7200 0.7101 0.7101 0.7101
Announcement Date 3/29/21 2/17/22 3/9/23 3/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - - -
EBITDA - -33.45 -51.79 -60.72 - - - -
EBIT 1 -38.97 -33.64 -52.23 -61.21 -39.9 -34.01 -74.72 -85.7
Operating Margin - - - - - - - -
Earnings before Tax (EBT) 1 - -34.84 -51.75 -61.62 -38.35 -33.67 -74.72 -85.7
Net income 1 - -34.84 -51.75 -61.62 -38.35 -32.68 -52.41 -65.65
Net margin - - - - - - - -
EPS 2 -420.7 -7.620 -2.050 -2.430 -1.440 -1.203 -1.815 -2.075
Free Cash Flow - -38.2 -52.53 -43.13 - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 9/2/20 3/29/21 2/17/22 3/9/23 3/8/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - -
EBITDA - - - - -13.36 - - - - - - - -
EBIT -13.47 - -17.12 -13.62 -13.52 -13.49 -11.16 -5.855 -6.671 - - - -
Operating Margin - - - - - - - - - - - - -
Earnings before Tax (EBT) -13.41 - - - - -12.99 -10.74 -8.136 -6.475 - - - -
Net income 1 -13.41 -16.94 -16.89 -13.73 -14.07 -12.99 -10.74 -8.136 -6.475 -5.477 -10.5 -4.8 -4.3
Net margin - - - - - - - - - - - - -
EPS 2 -0.5300 -0.6700 -0.6700 -0.5400 -0.5500 -0.5100 -0.4100 -0.3000 -0.2300 -0.2000 -0.2500 -0.1350 -0.1150
Dividend per Share - - - - - - - - - - - - -
Announcement Date 2/17/22 4/29/22 7/29/22 11/8/22 3/9/23 4/28/23 7/31/23 11/6/23 3/8/24 4/29/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 164 62.6 32.8 - 18.1 71.7 109
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow -38.2 -52.5 -43.1 - - - -
ROE (net income / shareholders' equity) -73.9% -36.6% -68.9% - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 6.550 4.640 2.430 - - - -
Cash Flow per Share -8.350 -2.070 -1.690 - - - -
Capex - 0.22 0.2 - - - -
Capex / Sales - - - - - - -
Announcement Date 3/29/21 2/17/22 3/9/23 3/8/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.7101 USD
Average target price
6 USD
Spread / Average Target
+744.95%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GALECTO, INC. Stock Galecto, Inc.
-0.07% 19.25M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 106B
ARGENX SE Stock argenx SE
+7.02% 23.47B
BIONTECH SE Stock BioNTech SE
-14.73% 21.9B
GENMAB A/S Stock Genmab A/S
-7.05% 18.77B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.55% 17.85B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.88% 16.78B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.71% 14.41B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.64% 12.86B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+316.86% 8.78B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GLTO Stock
  4. Financials Galecto, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW